Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q3 2020 Earnings Presentation

41 slides from Reata Pharmaceuticals's earnings presentation, Nov 9, 2020

  1. Slide 1: Management Call: Third Quarter 2020 Earnings

    Management Call CARDINAL Year 2 Data EAGLE Year 3 Data MOXIe Baseline-Controlled Study Data Third Quarter 2020 Earnings NOV 9.2020 Exhibit 99.3

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement

  3. Slide 3: Today's Agenda

    Today’s Agenda Opening Remarks | Warren Huff, CEO Clinical Updates | Colin Meyer, MD, Chief R&D Officer CARDINAL Year 2 Phase 3 study results EAGLE long-term efficacy data MOXIe Baseline-Controlled study Financial & Operational Update | Manmeet Soni, COO & CFO Concluding Remarks | Warren Huff, CEO

  4. Slide 4: CARDINAL Year 2 Data and EAGLE Year 3 Data

    CARDINAL Phase 3 YEAR 2 Data EAGLE Year 3 Data

  5. Slide 5: Efficacy Conclusions

    Efficacy Conclusions cycle CARDINAL met its Year 2 primary endpoint (p=0.0005) eGFR improvements continued in 2nd and 3rd year of treatment CARDINAL met its Year 2 key secondary endpoint (p=0.023) Treatment benefit observed in multiple subgroups Composite of kidney failure events was reduced by 50%

  6. Slide 6: Safety Conclusions

    Safety Conclusions AE Profile is consistent with prior trials Majority of AEs were mild to moderate in severity Approximately 50% fewer Bard patients reported SAEs UACR not increased relative to placebo after two years Fewer non-kidney AEs associated with Alport in Bard patients Changes in weight, B

  7. Slide 7: Alport Syndrome is a Severe, Inherited Form of CKD

    Alport Syndrome is a Severe, Inherited Form of CKD 30,000 - 60,000 in the US6 32,000 - 64,000 in the EU6 1USRDS (2014), 2Jais et al., JASN (2000); 3Kashtan et al., Kidney Int (2018); 4Kruegel et al., Nat Rev Nephrol (2013); 5Gomez et al., JCI (2015); 6Estimated based on Persson et al., Clin Nephrol

  8. Slide 8: Burden of Disease in Alport Syndrome

    1Kashtan et al., Kidney Int (2018); 2Jais et al., JASN (2000); 3NKF-ASF-FDA Voice of the Patient Externally Led Patient-Focused Drug Development Meeting on Alport Syndrome, August 3, 2018; 4CARDINAL Phase 3 historical eGFR decline rate Burden of Disease in Alport Syndrome Up to 100% Lifetime risk fo

  9. Slide 9: CARDINAL Phase 3: Pivotal Study Design

    CARDINAL Phase 3: Pivotal Study Design International, randomized, double-blind, placebo-controlled, registrational, two-year trial Largest and longest interventional study in patients with AS Enrolled a wide and representative range of patients with AS eGFR: 30 to 90 mL/min Age: 12 to 70 years Prima

  10. Slide 10: CARDINAL: Disposition

    CARDINAL: Disposition KEYWORD Placebo Bard ITT Population 80 77 Completed Year 1 71 (89%) 60 (78%) Received dose in Year 2 69 (86%) 58 (75%) Completed treatment through Week 100 67 (84%) 51 (66%) Completed follow-up through Week 104 79 (99%) 75 (97%) Discontinuations for Bard patients were higher th

  11. Slide 11: CARDINAL Met Year 2 Primary and Key Secondary Endpoints

    CARDINAL Met Year 2 Primary and Key Secondary Endpoints Randomization was stratified by baseline urinary albumin to creatinine ratio (UACR) category (≤300; >300 to 1000; >1000 to 3500). The difference between Bard and placebo is estimated using a model with baseline eGFR, UACR stratification, and fr

  12. Slide 12: CARDINAL: eGFR Increase with Bard Continued in Year 2

    Year 1 Year 2 4 week Off-Treatment CARDINAL: eGFR Increase with Bard Continued in Year 2 Data plotted are observed mean changes from baseline in eGFR. Changes in eGFR in Year 2 eGFR are calculated relative to Year 1 Baseline. 1 Intent-to-treat (ITT) analysis includes eGFR values for patients who rem

  13. Slide 13: EAGLE Extension: Bard Patients with eGFR Data at Year 3

    4 week Off-Treatment 4 week Off-Treatment EAGLE Extension: All Bard Patients with eGFR Data at Year 3 Year 1 Baseline Week 48 Change 61.8 ± 20.9 11.5 ± 8.3 Year 2 Week 52 (Year 2 Baseline) Week 100 Change 67.3 ± 26.9 13.3 ± 9.6 Year 3 Week 104 (Year 3 Baseline) Week 152 Change 64.1 ± 25.6 11.0 ± 14.

  14. Slide 14: Bard Reduced Risk of Kidney Failure Event Composite

    Bard Reduced Risk of Kidney Failure Event Composite Bard reduced the risk by 50% of a kidney failure event composite defined as: ESKD, Confirmed 30% eGFR decline, or Confirmed eGFR < 15 mL/min/1.73 m2 Hazard ratio=0.49 p=0.086 Probability of No Event

  15. Slide 15: Pre-specified Subgroups Favored Bard

    Pre-specified Subgroups Favored Bard Favors Placebo Favors Bard On-treatment and off-treatment benefit with Bard compared to Placebo observed in multiple subgroups and across multiple stages of disease Efficacy observed on top of standard of care ACEi/ARB therapy Week 100 Difference (Bardoxolone Met

  16. Slide 16: Treatment Effect in Pediatric Patients

    Treatment Effect in Pediatric Patients eGFR Change from Baseline Mean± SEM, mL/min/1.73 m2 Placebo Bard Week 100 and Week 104 eGFR changes for pediatric subpopulation analyzed using the same methodologies described for overall ITT population. p=0.004 p=0.017 Difference (Bard ─ Placebo) Week 100 13.8

  17. Slide 17: Adverse Event Overview

    Adverse Event Overview Placebo (n=80) Bard (n=77) Number of Patients with AE 77 (96%) 75 (97%) Number of Patients with SAE 15 (19%) 8 (10%) Pediatric Patients with SAE 2 (3%) 0 Discontinuations due to AEs 4 (5%) 10 (13%) No Deaths SAEs in patients treated with Bard: Approximately half the rate of pl

  18. Slide 18: Adverse Events Reported in >10% of Patients

    Adverse Events Reported in > 10% of Patients Placebo (n=80) Bard (n=77) Muscle spasms 27 (34%) 38 (49%) Alanine aminotransferase increased 2 (3%) 36 (47%) Aspartate aminotransferase increased 1 (1%) 19 (25%) Nasopharyngitis 24 (30%) 18 (23%) Headache 16 (20%) 16 (21%) Fatigue 12 (15%) 14 (18%) Nause

  19. Slide 19: No Changes in Blood Pressure or Fluid-Overload Adverse Events

    No Changes in Blood Pressure or Imbalances in Fluid-Overload Adverse Events Blood pressure, a sensitive measure of fluid status, was unchanged relative to placebo No imbalances in AEs associated with fluid status, including hypertension or peripheral edema No SAEs of fluid-overload in patients treat

  20. Slide 20: UACR Not Increased Relative to Placebo at Year 2

    UACR Not Increased Relative to Placebo at Year 2 Early UACR increases accounted for by eGFR increases UACR not significantly different than placebo at Weeks 100 and 104 Baseline Week 12 Week 48 Week 100 Week 104 Placebo 134.5 (33.4) 133.4 (33.8) 141.6 (38.5) 186.1 (53.8) 166.1 (47.7) Bard 148.1 (34.

  21. Slide 21: Non-Kidney Symptoms Associated with Alport Syndrome

    Non-Kidney Symptoms Associated with Alport Syndrome Percentage of Patients Placebo Bard Non-kidney AEs associated with Alport syndrome, including psychiatric, hearing and vestibular, and ocular, occurred less frequently in Bard patients

  22. Slide 22: Other Review Topics

    Other Review Topics Key Question Supporting Data Profile of eGFR and UACR inconsistent with kidney injury Bard reduced risk for adverse kidney outcomes in CARDINAL Patients who discontinued Bard similar to placebo after 2 years ISS dataset (>3000 patients) validate resolution of off-treatment eGFR c

  23. Slide 23: Conclusions

    Conclusions cycle Alport syndrome is a rare, severe disease with no approved therapies Primary and key secondary efficacy endpoints were met at Year 1 and Year 2 CARDINAL was the largest interventional trial conducted in patients with Alport syndrome Bard had favorable safety profile Clinically mean

  24. Slide 24: Regulatory Update

    Regulatory Update We recently completed pre-NDA meeting with the FDA to discuss NDA submission and content plans We received feedback on questions regarding our submission plan for clinical data, clinical pharmacology data, nonclinical data, CMC, and other topics FDA confirmed our NDA content and da

  25. Slide 25: Impact of Global COVID-19 Pandemic

    Impact of Global COVID-19 Pandemic COVID- Related Challenges Varying lockdown periods across geographies CKD patients are at risk of severe illness1 Travel restrictions and study site closures limited in-person visits Operational Changes to CARDINAL Modified visit windows to increase scheduling flex

  26. Slide 26: Thank You

    THANK YOU to patients, caregivers, investigators, and site staff for their participation

  27. Slide 27: Omaveloxolone Baseline-Controlled Study

    Omaveloxolone Baseline-Controlled Study

  28. Slide 28: Objective and Overview of Baseline-Controlled Study

    Objective and Overview of Baseline-Controlled Study Baseline-controlled study (cross-over study) assessed the strength and certainty of the positive primary endpoint findings in MOXIe Part 2 Treatment-naïve patients from MOXIe Part 1 and Part 2 served as their own controls to assess changes in mFARS

  29. Slide 29: Overview of Design

    Overview of Design Primary efficacy endpoint: paired difference in annualized mFARS slope for treatment period vs pre-treatment period Primary analysis population: Part 1 patients and Part 2 placebo patients without pes cavus who had an mFARS assessment at Week 48 of MOXIe Extension (n=34) Multiple

  30. Slide 30: Baseline-Controlled Study mFARS Results Demonstrate Significance

    Baseline-Controlled Study mFARS Results Demonstrate Significance Across All Analysis Populations Primary Analysis: -3.76 improvement in mFARS (p-value=0.0022) All analysis populations demonstrated a statistically significant treatment effect All populations showed worsening during pre-treatment peri

  31. Slide 31: All Sensitivity Analyses Demonstrated a Significant Treatment Effect

    All Sensitivity Analyses Demonstrated a Significant Treatment Effect All pre-specified and post-hoc sensitivity analyses demonstrated significant treatment effect and upheld primary analysis conclusions Sensitivity Analysis Contributing Data (n) mFARS Slope, Mean (SE) Pre-treatment Treatment Differe

  32. Slide 32: Baseline-Controlled Study Conclusions

    Baseline-Controlled Study Conclusions Study met its primary endpoint (p=0.0022) All sensitivity analyses showed a significant treatment effect Additional categorical analyses demonstrated robustness of results and unlikely due to chance We believe the results of the baseline-controlled study support

  33. Slide 33: Omaveloxolone Regulatory Update

    Omaveloxolone Regulatory Update In our Type C Meeting, Dr. Dunn, the Director of the Office of Neuroscience at the FDA, acknowledged that it would consider all opportunities to increase the persuasiveness of the MOXIe Part 2 results A cross-over design utilizing the ongoing long term extension study

  34. Slide 34: Financial & Operational Update

    Financial & Operational Update

  35. Slide 35: Financial Update

    Financial Update Current cash balance of $578.3 million as of September 30, 2020 Cash expected to be sufficient to fund operations through end of 2023 September 31, 2020 December 31, 2019 (in thousands) (unaudited) Cash and Cash Equivalents $,578,263 $,664,324 Condensed Statements of Operations Thre

  36. Slide 36: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures Three Months Ended September 30 Nine Months Ended September 30 (unaudited, in thousands, except per share data) 2020 2019 2020 2019 Reconciliation of GAAP to Non-GAAP Research and development: GAAP Research and development $37,183 $32,279 $,121,6

  37. Slide 37: Preparation for Launch Success

    Preparation for Launch Success Strategic Priorities & Launch Objectives Launch Ready at FDA Approval Strategic Priorities Corporate Value Disease Awareness Product Access Organizational Readiness Physicians and patients are convinced of Reata’s commitment to Nephrology and Neurology Physicians, pati

  38. Slide 38: Concluding Remarks

    | | Concluding Remarks

  39. Slide 39: Deep Pipeline with Two Pre-Registration Programs and Another Pivotal Study Ongoing

    Deep Pipeline with Two Pre-Registration Programs and Another Pivotal Study Ongoing 1Ex-Asia for bardoxolone Autoimmune Indications | RTA 1701 *NDA submission planned for 1Q21 **Subject to discussion with regulatory authorities DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PIVOTAL NDA CKD Caused by Alport Sy

  40. Slide 40: Reata at a Glance

    Reata at a Glance Chronic Kidney Disease Franchise Positive Year 2 data for Bard in Alport syndrome NDA planned for 1Q21 Pipeline in rare forms of CKD FALCON study in ADPKD ongoing Positive proof-of-concept data in FSGS, IgAN, and T1D CKD Neurology Franchise Positive pivotal data and Baseline-Contro

  41. Slide 41: Q&A

    a 4. Q&A

Reata Pharmaceuticals — Q3 2020 Earnings Presentation on 6ix